Clinical trial · Interventional
Characterisation of the Immune Infiltrate and Molecular Features of Thymic Epithelial Tumors Tumors (TETs)
NCT05558644CI-TRIAL-00117531IMMUNO-TETrecruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The IMMUNO-TET trial aims to assess the feasibility of characterising the immune environment of TETs and the constitutional and somatic molecular profiles of patients with localised thymic epithelial tumour (TET).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| single arm for all patients | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- single arm for all patients
- description
- single arm for all patients tumor samples will be taken for RNA sequencing of epithelial tumour cells during surgery. blood samples will be taken for Exome Sequencing (WES) at baseline, during surgery and one month post surgery.
- interventionNames
- Other: single arm for all patients
Primary outcomes (3)
- measure
- Somatic molecular characterisation of TETs
- timeFrame
- 38 months
- description
- Description of genetic abnormalities in thymic tumours compared to non-tumourous thymic tissue (Whole Exome Sequencing RNA-sequencing technique, DNA Optical mapping);
- measure
- Characterisation of the immune environment of TETs
- timeFrame
- 38 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patient with suspicion of localised thymic epithelial tumour. 2. Age ≥ 18 years. 3. Treatment-naïve patient for this disease. 4. Patient with an indication for thymectomy and thymomectomy in one of the partner centers. 5. Signed informed consent form of the patient. Exclusion Criteria: 1. Neoadjuvant chemotherapy. 2. No social security affiliation. 3. Person under legal protection. 4. Other neoplasia in progress or cured within the last 3 years (except for operated carcinoma in situ).
References
Publications (0)
Data not yet available
No reference posted for this study.